Edition:
United Kingdom

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

25.66USD
13 Dec 2017
Change (% chg)

$0.84 (+3.38%)
Prev Close
$24.82
Open
$24.80
Day's High
$25.80
Day's Low
$24.80
Volume
477,429
Avg. Vol
341,874
52-wk High
$32.22
52-wk Low
$16.51

Latest Key Developments (Source: Significant Developments)

Flexion Therapeutics Acquires Rights To Genequine Biotherapeutics' Non-Opioid Drug
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Flexion Therapeutics Inc ::FLEXION THERAPEUTICS ANNOUNCES ACQUISITION OF NOVEL, NON-OPIOID ASSET FOR OSTEOARTHRITIS OF THE KNEE.FLEXION THERAPEUTICS INC - ENTERED INTO A DEFINITIVE AGREEMENT WITH GENEQUINE BIOTHERAPEUTICS GMBH TO ACQUIRE GLOBAL RIGHTS TO GQ-20.FLEXION THERAPEUTICS - CO OBTAINED EXCLUSIVE LICENSE TO UNDERLYING INTELLECTUAL PROPERTY RIGHTS FOR HUMAN USE OF GQ-203 FROM BAYLOR COLLEGE OF MEDICINE.FLEXION THERAPEUTICS - CO TO MAKE UPFRONT PAYMENT OF $2 MILLION TO GENEQUINE & MAY INCUR MILESTONE PAYMENTS OF UP TO $8.7 MILLION THROUGH PHASE 2 POC.  Full Article

Flexion therapeutics reports third-quarter results
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics reports third-quarter 2017 financial results and recent business highlights.Flexion Therapeutics Inc - qtrly basic and diluted net loss per share $1.07‍​.  Full Article

Flexion Therapeutics announces pricing of public offering of common stock
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces pricing of public offering of common stock.Says public offering of 4.80 million common shares priced at $25.50per share.  Full Article

Flexion Therapeutics- Proposed public offering of 4 mln common shares
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces proposed public offering of common stock.Says offering 4.00 million common shares.Flexion Therapeutics Inc - Flexion intends to use net proceeds from offering to fund manufacturing and commercialization of Zilretta(TM)​.  Full Article

Flexion Therapeutics announces FDA approval of Zilretta for osteoarthritis knee pain
Friday, 6 Oct 2017 

Oct 6 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces FDA approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis (OA) knee pain.Says ‍product label also includes positive data from type 2 diabetes study​.Says ‍commercial supply expected to be available by late October following recent completion of manufacturing process validation​.  Full Article

Flexion Therapeutics submits new drug application for Zilretta to treat knee osteoarthritis pain
Monday, 12 Dec 2016 

Flexion Therapeutics Inc :Submits new drug application for Zilretta to treat knee osteoarthritis pain.  Full Article

Flexion's drug, Zilretta, meets main goal in mid-stage study
Tuesday, 1 Nov 2016 

Flexion Therapeutics Inc :Flexion Therapeutics reports primary endpoint met in clinical trial evaluating investigational drug candidate zilretta™ in type 2 diabetes patients with knee osteoarthritis.  Full Article

Flexion Therapeutics reports Q2 2016 financial results
Wednesday, 3 Aug 2016 

Flexion Therapeutics : Reports Second Quarter 2016 financial results . Reported a net loss of $14.2 million for Q2 of 2016, compared to a net loss of $12.4 million for Q2 of 2015 .Following positive guidance from U.S. FDA planned New Drug Application (NDA) submission on track for Q4 of 2016.  Full Article

Flexion Therapeutics announces pricing of public offering of common stock
Wednesday, 8 Jun 2016 

Flexion Therapeutics Inc : Flexion Therapeutics announces pricing of public offering of common stock .Says public offering of 5.50 mln common shares priced at $14.00/shr.  Full Article

Flexion Therapeutics expects to incur "significant losses for foreseeable future"
Tuesday, 7 Jun 2016 

Flexion Therapeutics Inc : Anticipate that we will continue to incur significant losses for foreseeable future .As of March 31, 2016, had an accumulated deficit of $156.6 million.  Full Article

BRIEF-Flexion Therapeutics Acquires Rights To Genequine Biotherapeutics' Non-Opioid Drug

* FLEXION THERAPEUTICS ANNOUNCES ACQUISITION OF NOVEL, NON-OPIOID ASSET FOR OSTEOARTHRITIS OF THE KNEE